MIMEDX GROUP, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $418.6M | $348.9M | $321.5M | $267.8M | $242.0M |
| Cost of revenue | $73.0M | $60.1M | $54.6M | $48.3M | $39.6M |
| Gross profit | $345.6M | $288.8M | $266.8M | $219.5M | $202.4M |
| Selling, general & administrative | $266.2M | $225.1M | $211.1M | $208.7M | $194.8M |
| Research and development | $15.1M | $12.3M | $12.7M | $12.7M | $9.9M |
| Operating income | $63.9M | $58.9M | $37.1M | -$14.7M | -$7.1M |
| Interest expense | $1.8M | $3.9M | $6.6M | $5.0M | — |
| Pretax income | $66.3M | $57.3M | $30.6M | -$19.7M | -$12.1M |
| Income tax expense | $17.7M | $15.3M | -$36.8M | $206,000 | $247,000 |
| Net income | $48.6M | $42.4M | $58.2M | -$30.2M | -$10.3M |
| Balance Sheet | |||||
| Cash and equivalents | $166.1M | $104.4M | $82.0M | $66.0M | $87.1M |
| Current assets | $277.5M | $191.9M | $164.3M | $134.2M | $148.5M |
| Total assets | $342.7M | $263.9M | $239.0M | $171.4M | $187.9M |
| Current liabilities | $64.3M | $45.6M | $46.0M | $43.6M | $42.4M |
| Total liabilities | $86.1M | $70.8M | $96.3M | $96.9M | $95.4M |
| Stockholders' equity | $256.5M | $193.1M | $142.7M | -$18.0M | $82,000 |
| Cash Flow Statement | |||||
| Cash from operations | $74.0M | $66.2M | $26.8M | -$17.9M | -$2.0M |
| Depreciation and amortization | $14.9M | $6.0M | $3.4M | $3.3M | $4.4M |
| Stock-based compensation | $16.4M | $16.9M | $17.0M | $11.3M | $14.2M |
| Capital expenditure | $0 | $0 | $2.0M | $1.5M | $3.2M |
| Free cash flow | $74.0M | $66.2M | $24.8M | -$19.4M | -$5.2M |
| Share repurchases | $0 | $0 | $9.5M | $0 | $0 |
| Impairments | — | — | $0 | $0 | $0 |
Shares outstanding 148.9M · Free float 68.6%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.